Literature DB >> 22001108

Nutrition, dietary supplements and adenocarcinoma of the prostate.

Christopher Schultz1, Mark Meier, Hans-Peter Schmid.   

Abstract

Three well-known and indisputable risk factors contribute to the development of prostate cancer, namely heredity, ethnic origin and increasing age. Geographic variations in incidence rates are considerable and it has, therefore, been suggested that environmental factors may also play a role. Migration studies clearly show that men with the same genetic background raised in different environments show a similar risk of developing the disease to those in their country of residency. Prostate cancer is a good candidate for studies on primary prevention thanks to specific features such as high prevalence, long latency, hormonal dependency, serum markers for monitoring (prostate-specific antigen) and histological precursor lesions (prostatic intraepithelial neoplasia). Nutritional factors that may influence the disease include total energy intake (as reflected by body mass index), dietary fat, cooked meat, micronutrients and vitamins (carotenoids, retinoids, vitamins C, D and E), fruit and vegetable intake, minerals (calcium, selenium), and phytoestrogens (isoflavonoids, flavonoids, lignans). Most published studies have been case-control analyses. The selenium and vitamin E cancer prevention trial (SELECT), however, was a population-based, prospective, randomized clinical trial that examined the effect of selenium and vitamin E alone or in combination on prostate cancer risk reduction. The trial was recently discontinued due to no evidence of benefit from either agent. Nevertheless, lifestyle changes can still be recommended for men at risk of developing clinical prostate cancer. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22001108     DOI: 10.1016/j.maturitas.2011.08.007

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

Review 1.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

2.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

3.  High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions.

Authors:  Sophie Bernichtein; Natascha Pigat; Thierry Capiod; Florence Boutillon; Virginie Verkarre; Philippe Camparo; Mélanie Viltard; Arnaud Méjean; Stéphane Oudard; Jean-Claude Souberbielle; Gérard Friedlander; Vincent Goffin
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

Review 4.  Advances and development of prostate cancer, treatment, and strategies: A systemic review.

Authors:  Sana Belkahla; Insha Nahvi; Supratim Biswas; Irum Nahvi; Nidhal Ben Amor
Journal:  Front Cell Dev Biol       Date:  2022-09-09

Review 5.  Mast cells as a potential prognostic marker in prostate cancer.

Authors:  Gianluigi Taverna; Guido Giusti; Mauro Seveso; Rodolfo Hurle; Piergiuseppe Colombo; Sanja Stifter; Fabio Grizzi
Journal:  Dis Markers       Date:  2013-11-11       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.